RenovoRx develops RenovoCath, a drug delivery device, and other drug and device combination products for healthcare providers. It last closed at $1.04 on Nov 17, up 11.23% on the day.
Only 1 firm rated RNXT in the past 90 days, not enough for a consensus
Average 12-month target
$15.00
▲ 1342.3% upside
Based on 1 analyst who set a price target on RNXT in the past 90 days. The average target is $15.00, with a high of $15.00 and a low of $15.00, compared with the last close of $1.04.
Low $15.00Avg $15.00High $15.00
Blue marker: last close $1.04
Highest target$15.00
Average target$15.00
Lowest target$15.00
Latest rating changes
Ascendiant CapitalTarget raised
Nov 9Buy$14.50 → $15
Ascendiant CapitalTarget raised
Aug 28Buy$14 → $14.50
Ascendiant CapitalMaintained
Jun 1Buy$14
Date
Firm
Action
Rating
Price target
Nov 9
Ascendiant Capital
Target raised
Buy
$14.50 → $15
Aug 28
Ascendiant Capital
Target raised
Buy
$14 → $14.50
Jun 1
Ascendiant Capital
Maintained
Buy
$14
Loading…
Technical Analysis
RNXT · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend
The stock is 19% below its 20 day and 34% below its 50 day average. It is 7% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the Pivot at $1.02, and the nearest resistance the Pivot R1 at $1.07.
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 13.7%/day
Key levels
$2.5952 week high+149.0%
$1.4050 day average+34.6%
$1.30100 day average+25.0%
$1.2320 day average+18.3%
$1.20Swing high (Aug 7)+15.4%
$1.11200 day average+6.7%
$1.07Pivot R1+2.9%
$1.04Last close
$1.02Pivot−1.9%
$0.98Pivot S1−5.8%
$0.88Swing low (Nov 6)−15.4%
$0.7352 week low−29.8%
Indicators
RSI (14)
38.55
Weak, oversold below 30
Neutral
MACD
-0.09
Below its signal line
Bearish
Stochastic
18.7
Near the bottom of its range
Oversold
ADX (14)
16.6
No clear trend
Williams %R
-76.1
Oversold below −80, overbought above −20
Neutral
CCI (20)
-141.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−19.4%
Change over 10 sessions
Bearish
ATR (14)
$0.14
Typical daily range, 13.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 27.4%/day
Key levels
$2.5952 week high+149.0%
$1.4050 day average+34.6%
$1.30100 day average+25.0%
$1.2320 day average+18.3%
$1.20Swing high (Aug 7)+15.4%
$1.11200 day average+6.7%
$1.07Pivot R1+2.9%
$1.04Last close
$1.02Pivot−1.9%
$0.98Pivot S1−5.8%
$0.88Swing low (Nov 6)−15.4%
$0.7352 week low−29.8%
Indicators
RSI (14)
44.72
Middle of its range
Neutral
MACD
0.02
Below its signal line
Bearish
Stochastic
11.4
Near the bottom of its range
Oversold
ADX (14)
28.2
Trending up
Williams %R
-90.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-77.3
Oversold below −100, overbought above 100
Neutral
Rate of change
−40.9%
Change over 10 sessions
Bearish
ATR (14)
$0.28
Typical daily range, 27.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RNXT
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how RNXT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow RNXT usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How RNXT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RNXT is in one of them and how their past RNXT trades turned out.
RenovoRx is a medical device company based in Mountain View, California. It develops RenovoCath, a proprietary drug delivery device sold as a standalone product, along with other products that combine drugs and devices. Its product candidates are still in clinical trials. Its customers are expected to include physicians, hospitals and other healthcare providers, whose care may be paid for by government programs and private insurers.